The clinical effect of Kanglaite injection/soft capsule sequential combined immunotherapy on advanced non-small cell lung cancer and its influence on immune function

Wang Yang; Liu Suxiao; Wang Yuanyuan

doi:10.3760/j.issn.1673-4777.2025.11.017

Abstract：Objective To investigate the effect of Kanglaite injection/soft capsule sequential combined immunotherapy on the survival and immune function of patients with advanced non-small cell lung cancer(NSCLC).Methods A total of 123 patients with advanced NSCLC admitted to the First Affiliated Hospital of Henan University of Traditional Chinese Medicine from June 2022 to June 2023 were selected as the research objects.The patients were divided into groups A,B and C by random number table method,with 41 cases in each group.The patients in group A were treated with immunotherapy and other conventional treatment,the patients in group B were treated with Kanglaite injection on the basis of group A,and the patients in group C were treated with Kanglaite soft capsule on the basis of group B,with 21 d as a course of treatment.The patients in the three groups were treated for 3 consecutive courses.The clinical efficacy,tumor marker levels,immune function indexes,quality of life scores,survival cycle,and incidence of adverse reactions were compared among the three groups.Results According to the exclusion criteria,2 cases were excluded from group A,2 cases from group B,and 1 case from group C,respectively.Finally,there were 39 cases in group A,39 cases in group B,and 40 cases in group C.The objective response rate and disease control rate in group C were higher than those in group A[50.0％(20/40)vs 30.8％(12/39),70.0％(28/40)vs 48.7％(19/39)](both P＜0.05).After treatment,the levels of tumor markers in the three groups were lower than those before treatment,and those in group C were lower than those in group A and group B,and those in group B were lower than those in group A(all P＜0.05).After treatment,the immune function indexes of patients in group A were better than those before treatment,CD4+,CD8+,CD4+/CD8+of patients in group B and group C were better than those before treatment,and those in group C were better than those in group A and group B,and those in group B were better than those in group A(all P＜0.05).After treatment,the quality of life scores of the three groups were higher than those before treatment.The scores of quality of life in group C and group B were higher than those in group A,and the scores of physiological status,social and family status,functional status and lung cancer related symptoms in group C were higher than those in group B(all P＜0.05).There were no significant differences in the median time to progression,median progression-free survival and median overall survival among the three groups(all P＞0.05).The incidences of adverse reactions in group B and group C were lower than that in group A(x2=6.129,P=0.046).Conclusion Kanglaite injection/soft capsule sequential combined immunotherapy has a significant effect on patients with advanced NSCLC,which can reduce the level of tumor markers,improve immune function,improve the quality of life,prolong the survival period of patients,and reduce the incidence of adverse reactions.